402 Sleep DisordersStandard dosageContraindicationsMain drug interactionsMain side effectsCost/Cost-effectivenessWake-promoting medicationsof benzodiazepines and benzodiazepine receptor agonists in shift workdisorder.Benzodiazepine and benzodiazepine receptor agonist medications are notapproved by the US Food and Drug Administration (FDA) for the specificpurposes of treating shift work disorder or jet lag. However, for short-terminsomnia, temazepam (7.5–30 mg) or zolpidem (5–10 mg) may be used atbedtime [35, 36]. Zopiclone is not available in the United States.Temazepam and zolpidem should be used with care in elderly and debilitatedpatients,andalcoholshouldnotbeusedwitheither.Withtemazepam, slow tapering of the medication should be performed priorto discontinuation because of a risk of seizure with abrupt cessation.Zolpidem is a pregnancy category C medication. Pregnancy is an absolutecontraindication to temazepam use because of its class X designation [35, 36].Central nervous system depressants may have an additive effect with temazepamand zolpidem. Oral contraceptive pills may increase the clearance oftemazepam, and probenecid may decrease its clearance [35, 36].The most frequently reported adverse effects of zolpidem are daytimedrowsiness, headache, and dizziness. Amnesia may occur with benzodiazepineand benzodiazepine receptor agonist medications, and non–rapid eyemovement (NREM) parasomnias such as sleep walking or sleep eating alsomay occur. The most <strong>com</strong>mon adverse effects of temazepam are headache,drowsiness, ataxia, dizziness, confusion, depression, syncope, fatigue, vertigo,and tremor. Patients should be monitored for physiologic dependenceon temazepam [35, 36].Both zolpidem and temazepam are less than $20 for a 30-day supply,making them cost-effective treatment options.Because night shift work occurs during a time of high propensity forsleep, wake-promoting medications have been investigated to improvealertness in shift workers.In one study, methamphetamine improved mood and performanceduring the night shift in simulated laboratory workers [37, Class II].However, because of the minimal evidence supporting its use and itspotential for abuse, this medication is not indicated in the treatment ofshift work disorder [11].In a randomized double-blind controlled trial, modafinil (200 mg)was given 30 to 60 min before the start of night shift work, resultingin objective improvement in sleepiness and improved performance onpsychomotor vigilance testing. In addition, there were 25% feweraccidents and near-accidents in the modafinil group than in the placebogroup (PG0.001). Despite these functional improvements andthe attenuation of sleepiness, a pathologic level of sleepiness similarto that of narcolepsy (mean sleep latency, 3.8 min) persisted in nightshift workers [38, ClassI].Armodafinil is the R isomer of modafinil and has a longer half life(15 h) than the S isomer of modafinil (3–4 h). In a 12-week randomizedcontrolled trial of 254 night shift and rotating shift workers with shiftwork disorder, 150 mg of armodafinil was given 30 to 60 min prior tobeginning the night shift. Armodafinil resulted in a significant increase in
Shift Work Disorder and Jet Lag Zee and Goldstein 403Standard dosageContraindicationsmean sleep latency <strong>com</strong>pared with placebo (3 min vs 0.4 min respectively).By self-report, armodafinil reduced sleepiness during work and on themorning <strong>com</strong>mute. Significant improvement in performance on standardizedmemory and attention testing was also demonstrated. No worsening indaytime sleep parameters occurred with armodafinil [39•, Class I].Modafinil and armodafinil are effective in promoting alertness duringnight shift work and are FDA-approved for the treatment of shift workdisorder.Modafinil (200 mg) or armodafinil (150 mg) taken approximately 1 h priorto shift work.Patients with cardiac signs or symptoms occurring in the setting of stimulantmedication should not take modafinil or armodafinil. Caution should beexercised in prescribing these medications for patients with a known historyof psychosis, unstable angina, or recent myocardial infarction, and thosewith seizures. Both drugs are FDA pregnancy category C [40, 41].Main drug interactions Modafinil and armodafinil may decrease the effectiveness of oral contraceptivepills and other drugs metabolized by the CYP3A4 isoenzyme, anddrugs inducing the CYP3A4 enzyme may increase the metabolism of modafiniland armodafinil [40, 41].Main side effects Rare but life-threatening rashes have occurred with modafinil therapy [40].Headache, nausea/vomiting, anxiety, nervousness, and insomnia were themost <strong>com</strong>mon adverse reactions occurring in clinical trials of modafinil [40].Headache, nausea/vomiting, dizziness, and insomnia were the most <strong>com</strong>monadverse reactions occurring in clinical trials of armodafinil [41]. Someindividuals taking armodafinil had a small elevation in blood pressure [41].CostThe retail price for a 30-day supply is $475.95 for modafinil (Provigil;Cephalon, Frazer, PA) and $304.97 for armodafinil (Nuvigil; Cephalon,Frazer, PA).Other treatmentsTimed bright light exposureTimed light exposure can be employed for its circadian phase shiftingeffects as well as its beneficial effects on alertness and cognitive performance[42]. The AASM suggests the use of timed light during the workperiod and restriction of morning light in night shift workers as a treatmentguideline [11].In field studies of shift workers, light regimens of 2350 to 12,000 luxfor durations of 20 minutes (with multiple exposures) to 6 h have shownimprovements in psychomotor performance, subjective alertness, andself-rated mood [43, 44, 45, Class III].Bright light exposure and the avoidance of light have been used topromote circadian shifts to move the core body temperature nadir fromthe work period to the sleep period. Studies using this treatment strategyhave been performed in both night work simulation and in field testingof actual night workers [5]. Bright light of 6000 to 12,000 lux during atleast half of a 12-hour night shift resulted in a significant phase shift in50% of shift workers receiving the treatment, <strong>com</strong>pared with controls
- Page 1 and 2:
Practice Management Tips ForSHIFT W
- Page 3 and 4:
Patient QuestionnaireDo you often f
- Page 5 and 6:
Sleep/Wake LogIn bedOut of bedLight
- Page 7 and 8:
PHQ-9 QUICK DEPRESSION ASSESSMENTFo
- Page 9 and 10:
Insomnia Severity IndexPlease answe
- Page 11 and 12:
Take-Away PointsSHIFT WORK DISORDER
- Page 13 and 14:
SHIFT WORKDISORDERBright Light Ther
- Page 40 and 41:
PrimarycareScreeningfor depressioni
- Page 42 and 43:
PrimarycareThescreening questionnai
- Page 44 and 45:
Shift-work disorderContents and Fac
- Page 46 and 47:
Shift-work disorderThe diagnosis of
- Page 48 and 49:
Shift-work disorderas heightened le
- Page 50 and 51:
Shift-work disorderFigure 1 Risk ra
- Page 52 and 53:
Shift-work disorderare not function
- Page 54 and 55:
The characterization andpathology o
- Page 56 and 57:
Shift-work disorderFigure 2 Sleep/w
- Page 58 and 59:
Shift-work disorderFigure 3 Blood p
- Page 60 and 61:
Recognition of shift-workdisorder i
- Page 62 and 63:
Shift-work disorderThe timing of sh
- Page 64 and 65:
Shift-work disorderthe other potent
- Page 66 and 67:
Managing the patient withshift-work
- Page 68 and 69:
Shift-work disorderFigure 3 Optimal
- Page 70 and 71:
Shift-work disorderfor a motor vehi
- Page 72 and 73:
Shift-work disordermoderate caffein
- Page 74 and 75:
Supplement toAvailable at jfponline
- Page 76 and 77:
Armodafinil for Treatment of Excess
- Page 78 and 79:
Armodafinil for Treatment of Excess
- Page 80 and 81:
Armodafinil for Treatment of Excess
- Page 82 and 83:
Armodafinil for Treatment of Excess
- Page 84 and 85:
Armodafinil for Treatment of Excess
- Page 86 and 87:
Armodafinil for Treatment of Excess
- Page 88 and 89:
Armodafinil for Treatment of Excess
- Page 90 and 91:
Armodafinil for Treatment of Excess
- Page 92 and 93:
Armodafinil for Treatment of Excess
- Page 94 and 95:
Armodafinil for Treatment of Excess
- Page 96 and 97:
Armodafinil for Treatment of Excess
- Page 98 and 99:
The Epidemiology and Diagnosis of I
- Page 100 and 101:
The Epidemiology and Diagnosis of I
- Page 102 and 103:
The Epidemiology and Diagnosis of I
- Page 120 and 121: CIRCADIAN RHYTHM SLEEP DISORDERSPra
- Page 122 and 123: Table 2— AASM Levels of Recommend
- Page 124 and 125: 3.2.1.1 Both the Morningness-Evenin
- Page 126 and 127: Five studies used one of the newer
- Page 128 and 129: as an indicator of phase in sighted
- Page 130 and 131: 4.4 Advanced Sleep Phase DisorderBe
- Page 132 and 133: 45. Walsh, JK, Randazzo, AC, Stone,
- Page 134: 123. Van Someren, EJ, Kessler, A, M
- Page 142 and 143: Table 1—Subject Demographicsn M:F
- Page 144 and 145: Scale. 28 The simple reaction time
- Page 146 and 147: Median RT (msec)1600A14001200100080
- Page 148 and 149: 10Mentally AExhaustedSharpScore8642
- Page 150 and 151: Current Treatment Options in Neurol
- Page 152 and 153: 398 Sleep Disordersand sleep loss,
- Page 154 and 155: 400 Sleep DisordersTable 1. Treatme
- Page 158 and 159: 404 Sleep DisordersStandard procedu
- Page 160 and 161: 406 Sleep DisordersCaffeineMelatoni
- Page 162 and 163: 408 Sleep DisordersWake-promoting a
- Page 164 and 165: 410 Sleep Disordersnight shift: ada